CClinicalTrials.gg
Sign In
CompletedNCT00630123Updated Dec 16, 2015

Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation(TMS) on Brain Derived Neurotrophic Factor (BDNF) in Depressed Patients.

An observational study in Depression, sponsored by Queen's University. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-12-16.

Sponsored by Queen's University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To investigate the change in brain derived neurotrophic factor (BDNF) between pre and post treatment for patients with depression with either ECT or TMS.

02

Conditions studied

  • Depression

Browse trials for

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 36 is below the median of 160 across 1,084 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Queen's University is the lead sponsor of 199 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults patients with current major depressive disorder or bipolar depression who are to receive either ECT or TMS.

Inclusion criteria

  • MDD or bipolar disorder;
  • current depressive episode, ham-d17>17 and ymrs\<8;
  • recommended to receive ECT or TMS as part of clinical care;
  • male/female;
  • age 18-65;
  • inpatient or outpatient;
  • comorbid dysthymic disorder, gad, or social anxiety will be included;
  • able to give written consent and agree.

Exclusion criteria

Exclusion Criteria:

  • current manic, hypomanic, or mixed episode, ymrs>7;
  • current schizophrenia, anorexia, bulimia, substance dependence (current within past 6 months excluding caffeine and nicotine);
  • TMS or ECT in the last 3 months;
  • any other primary diagnosis;
  • uncontrolled medical illness;
  • epilepsy or severe personality disorder at the discretion of the investigators;
  • 3 weeks prior to first blood test, antidepressants, mood stabilizers, antipsychotics can not be added or increased;
  • pregnant women or women of childbearing potential not willing to use appropriate contraception, nursing women;
  • known intolerance or lack of response to treatment receiving as judged by the investigator;
  • medical conditions that would affect serum levels of BDNF;
  • involvement in planning and conduct of the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • 1

    Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.

  • 2

    Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.

06

What researchers measure

Primary outcomes

  1. Serum levels of BDNF.

    Time frame: pre and post treatment

Secondary outcomes

  1. Correlation between the change in BDNF levels and illness severity after treatment.

    Time frame: pre and post treatment

07

Study locations

1 site
  • Providence Care Mental Health Services
    Kingston, Ontario K7L4X3, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00630123
Lead sponsor
Queen's University
Responsible party
Dr. Roumen Milev (Principal Investigator, Queen's University) — Principal investigator
First posted
Mar 6, 2008
Start date
Nov 2006
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Dec 16, 2015

Study contacts

Roumen Milev, MD, FRCP(C)
principal investigator · Queen's University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Depression→

Other studies from this sponsor

Queen's University

Start the discussion